IRulya Therapeutics QNCX
NASDAQ QNCX
$34.45 +2.42 (+7.56%)
At close: Oct 19, 2026 · 4:00 PM EDT

Quince Therapeutics, Inc. (QNCX) Preferred Stock Liabilities (2018 - 2019)

Updated

Quince Therapeutics (QNCX) recorded Preferred Stock Liabilities of $104.14 million in Q1 2019, up 506.2% from $17.18 million a year earlier and up 0.1% from the prior quarter.

Analysis

Quince Therapeutics, Inc. (QNCX) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

At the end of FY2018, Quince Therapeutics reported Preferred Stock Liabilities of $104.05 million.

  • Per Business Quant, the preceding three quarters came in at $104.05 million (Q4 2018), $103.95 million (Q3 2018) and $103.89 million (Q2 2018).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 104.14 Mn
Dec 31, 2018 104.05 Mn
Sep 30, 2018 103.95 Mn
Jun 30, 2018 103.89 Mn
Mar 31, 2018 17.18 Mn
API Access

Quince Therapeutics, Inc. Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=QNCX&period=max&api_key=YOUR_API_KEY